Nasdaq iShares Biotechnology ETF (IBB) Elliott Wave analysis [Video]
Function: Major Trend. Mode: Motive. Structure: Triangle. Position: Wave [4].
Source link
Function: Major Trend. Mode: Motive. Structure: Triangle. Position: Wave [4].
Source link
COT | Data | Leaders | What is COT? | Excel | COT Dashboard Here are the latest links to our coverage of the Commitment of Traders data changes. Data updated through May 18th. The COT currency market speculator bets were overall lower this week as just three out of the eleven currency markets we…
By RoboForex Analytical Department EUR/USD reached 1.2000 on Wednesday after rising to 1.2082 the previous evening, marking a strong four-day rally. The pressure on the US dollar has intensified following comments from US President Donald Trump. He stated that he was not concerned about the weakening of the dollar, viewing its fall as moderate. The…
Interactive Brokers reported a sharp increase in trading activity for April 2025, with Daily Average Revenue Trades (DARTs) rising 10% month-on-month and 63% year-on-year to 3.818 million. In its brokerage metrics report for April, the broker said client activity remained robust across the platform. The number of client accounts reached 3.71 million, up 32% from…
Dow Jones – 27.09.2024 – Orbex Forex Trading Blog XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX;visibility:hidden”> Source link
FYNXT CEO Samuel Aeby: Why Brokers Need Operating Systems, Not Just CRMs FYNXT CEO Samuel Aeby: Why Brokers Need Operating Systems, Not Just CRMs FYNXT CEO Samuel Aeby: Why Brokers Need Operating Systems, Not Just CRMs FYNXT CEO Samuel Aeby: Why Brokers Need Operating Systems, Not Just CRMs FYNXT CEO Samuel Aeby: Why Brokers Need…
Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumor Pivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented efficacy and tolerability; vorasidenib granted priority review with PDUFA date of August 20, 2024 Royalty Pharma projects greater than $1 billion in peak sales annually for vorasidenib in…